Stockscreener 앱 받기
6.31
5.26%
-0.35
Karyopharm Therapeutics Inc 주식(KPTI)의 최신 뉴스
Aug Spikes: Can Karyopharm Therapeutics Inc disrupt its industryDividend Hike & Verified Entry Point Signals - baoquankhu1.vn
Chart Watch: Will Karyopharm Therapeutics Inc outperform its industry peersJuly 2025 Intraday Action & Technical Pattern Alert System - baoquankhu1.vn
Options Flow: Will Karyopharm Therapeutics Inc 25K0 stock rise with strong economyWeekly Risk Summary & Safe Entry Zone Tips - Bộ Nội Vụ
Layoff Watch: What margin trends mean for Karyopharm Therapeutics Inc stockWeekly Stock Analysis & Accurate Intraday Trading Signals - Bộ Nội Vụ
Analysts Are Bullish on Top Healthcare Stocks: Karyopharm Therapeutics (KPTI), Establishment Labs Holdings (ESTA) - The Globe and Mail
Karyopharm expects phase 3 trial data in myelofibrosis by March - Investing.com Nigeria
Karyopharm Therapeutics (NASDAQ:KPTI) Stock Crosses Above Fifty Day Moving AverageWhat's Next? - MarketBeat
Karyopharm Issues Preliminary 2025 Financial Results and Outlook - TipRanks
Karyopharm (KPTI) Anticipates Transformative 2026 with Key Trial Data - GuruFocus
Karyopharm Therapeutics reports preliminary 2025 revenue of $145 mln - TradingView — Track All Markets
Karyopharm Announces Preliminary Unaudited 2025 Revenue and Reiterates Expectation of Delivering Potentially Transformative Phase 3 Data in 2026 - PR Newswire
Karyopharm Therapeutics Inc.'s (NASDAQ:KPTI) Prospects Need A Boost To Lift Shares - simplywall.st
Is Karyopharm Therapeutics Inc. stock attractive for passive investorsJuly 2025 EndofMonth & Low Drawdown Investment Ideas - Улправда
Why Karyopharm Therapeutics Inc. (25K0) stock could rally stronglyQuarterly Growth Report & Verified Momentum Watchlists - Улправда
Is Karyopharm Therapeutics Inc. stock supported by innovation pipelineEarnings Trend Report & Risk Controlled Swing Alerts - ulpravda.ru
How Karyopharm Therapeutics Inc. stock performs in weak economy2025 Trade Ideas & AI Forecasted Entry and Exit Points - Улправда
Will Karyopharm Therapeutics Inc. (25K0) stock rise with strong economyMarket Growth Summary & Scalable Portfolio Growth Ideas - Улправда
Why Karyopharm Therapeutics Inc. stock attracts global investorsRate Hike & High Accuracy Investment Entry Signals - Улправда
Is Karyopharm Therapeutics Inc. stock attractive for income investorsPortfolio Gains Report & Fast Momentum Entry Tips - Улправда
Will Karyopharm Therapeutics Inc. stock remain a Wall Street favoriteTrend Reversal & Daily Chart Pattern Signals - Улправда
Karyopharm Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView — Track All Markets
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PR Newswire
Cancer therapy company Karyopharm gives new hires 3-year stock grants - Stock Titan
MACD Signal: Why Karyopharm Therapeutics Inc stock attracts global investors2025 Winners & Losers & Safe Capital Growth Tips - Bộ Nội Vụ
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
KPTI (Karyopharm Therapeutics Inc) has impressive results - uspostnews.com
Karyopharm Therapeutics (FRA:25K0) EV-to-OCF : -2.79 (As of Dec. 22, 2025) - GuruFocus
Why Karyopharm Therapeutics Inc. (25K0) stock could be next leader2025 Earnings Impact & Growth Focused Investment Plans - Улправда
Can Karyopharm Therapeutics Inc. stock resist sector downturnsJuly 2025 Market Mood & High Accuracy Trade Alerts - Улправда
Is Karyopharm Therapeutics Inc. stock a bargain at current levelsIndustrial Stocks Review & Free Extraordinary Earning Power - bollywoodhelpline.com
How Karyopharm Therapeutics Inc. stock responds to policy changesWeekly Trend Summary & Fast Entry Momentum Alerts - DonanımHaber
Can Karyopharm Therapeutics Inc. stock withstand economic slowdownJuly 2025 Gainers & Precise Swing Trade Entry Alerts - DonanımHaber
Will Karyopharm Therapeutics Inc. (25K0) stock beat international competitionQuarterly Portfolio Review & Accurate Entry/Exit Alerts - Улправда
Piper Sandler names Karyopharm stock as 2026 top pick, maintains $12 target - Investing.com Canada
Karyopharm Therapeutics’ Earnings Call: Progress Amid Challenges - MSN
Karyopharm Therapeutics (NASDAQ:KPTI) Stock Price Passes Above 50-Day Moving AverageHere's What Happened - MarketBeat
Karyopharm to Participate in Baird's Biotech Discovery Series - Karyopharm
Karyopharm (Nasdaq: KPTI) to discuss myelofibrosis in Baird Biotech Discovery Series chat - Stock Titan
Published on: 2025-12-10 09:05:07 - earlytimes.in
Karyopharm Therapeutics (KPTI) Price Target Decreased by 11.70% to 14.11 - MSN
Is Karyopharm Therapeutics Inc. (25K0) stock among top earnings plays2025 Technical Overview & Safe Capital Growth Tips - Newser
How Karyopharm Therapeutics Inc. (25K0) stock reacts to new regulationsTrade Volume Summary & Daily Stock Trend Watchlist - Newser
What makes Karyopharm Therapeutics Inc. (25K0) stock appealing to growth investorsJuly 2025 Volume & Fast Exit and Entry Strategy Plans - Newser
Will Karyopharm Therapeutics Inc. (25K0) stock outperform global peersJuly 2025 PostEarnings & Real-Time Buy Zone Alerts - Newser
Will Karyopharm Therapeutics Inc. (25K0) stock split increase liquidity2025 Big Picture & Fast Gaining Stock Reports - Newser
Will Karyopharm Therapeutics Inc. (25K0) stock announce special dividendMarket Growth Summary & Expert Curated Trade Ideas - Newser
Why global investors buy Karyopharm Therapeutics Inc. (25K0) stockJuly 2025 Highlights & AI Based Buy/Sell Signal Reports - Newser
Karyopharm Therapeutics (KPTI) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
4.73%
0.92%
자본화:
|
볼륨(24시간):